Search companies

Live

Tuesday, 17 November 2026 · 578 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

PYC Advances Four Genetic-Disease Drug Programs, With Kidney Trial Data Expected Next Year

PYC: $1.93 -1.78% · MC: $1.9B

PYC Therapeutics reported progress across four drug programs, including advancing its Phelan-McDermid candidate into required toxicology studies and moving its kidney-disease candidate into higher-dose and longer-term studies. The company said data from the ongoing kidney studies is expected in 2027, while early exploratory results from a single-dose study were presented after the quarter.

Source announcements: 2026-10-29 08:38 to 2026-10-29 08:38 Sydney time
Story updated 2026-10-29 08:45 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments